1
|
Andrini E, Lamberti G, Mazzoni F, Riccardi F, Bonetti A, Follador A, Giardina D, Genova C, Guaitoli G, Frassoldati A, Brighenti M, Colantonio I, Pasello G, Ficorella C, Cinieri S, Tiseo M, Gelsomino F, Tognetto M, Rihawi K, Ardizzoni A. EP14.01-006 CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open 2020; 6:100019. [PMID: 33399082 PMCID: PMC7808100 DOI: 10.1016/j.esmoop.2020.100019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 11/07/2020] [Accepted: 11/17/2020] [Indexed: 12/21/2022] Open
Abstract
Background The combination of a microtubule inhibitor (eribulin) with a nucleoside analog (gemcitabine) may synergistically induce tumor cell death, particularly in triple negative breast cancer (TNBC) characterized by high cell proliferation, aggressive behavior, and chemo-resistance. Patients and methods This is an open-label, multicenter phase II study evaluating the combination of eribulin (0.88 mg/m2) plus gemcitabine (1000 mg/m2) on days 1 and 8 of a 21-day cycle as either first- or second-line treatment of locally advanced or metastatic TNBC. The primary endpoint was the objective response for evaluable patients. A prospective, molecular correlative study was carried out to assess the role of germinal BRCA pathogenic variants and single nucleotide polymorphisms (SNPs) in predicting efficacy and toxicity of the combination regimen. Results From July 2013 to September 2016, 83 evaluable patients were enrolled. They received a median number of six cycles of treatment. An overall response rate (ORR) of 37.3% (31 patients) was observed, with a complete response rate of 2.4% and a partial response rate of 34.9%; the clinical benefit rate was 48.8%. With a median follow-up of 28.8 months, the median response duration was 6.6 months, the median progression-free survival (PFS) was 5.1 months, and the median overall survival (OS) was 14.5 months. The most common grade 3-4 adverse events were aminotransferase elevation (in 25% of the patients) and neutropenia (in 23.8%). Women with BRCA1/2 pathogenic variants were associated with worse ORR, PFS, and OS than BRCA1/2 wild-type carriers. CYP3A4 and FGD4 SNPs were associated with increased risk of liver toxicity. Three different SNPs in CDA∗2, RRM1, and CYP2C8 genes were significantly associated with poorer OS. Conclusions The combination of eribulin and gemcitabine showed promising activity and a moderate toxicity profile in metastatic TNBC. BRCA status and pharmacogenetics tests may help identify patients with high probability of response with negligible toxicity. EudraCT number 2012-003505-10. Eribulin plus gemcitabine showed a remarkable best ORR of 37.3% and a clinical benefit rate of 48.8%. The most common grade 3/4 toxicities were liver toxicity and neutropenia without febrile neutropenia. The study regimen partially lost its efficacy in patients harboring BRCA1/2 pathogenic variants. SNPs in CYP3A4 and FGD4 genes were associated with increased risk of liver toxicity. Three different SNPs in CDA∗2, RRM1, and CYP2C8 genes were significantly associated with poorer OS.
Collapse
Affiliation(s)
- B Pellegrino
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - L Cavanna
- Hospital of Piacenza, Piacenza, Italy
| | - D Boggiani
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy
| | - C Zamagni
- SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - A Frassoldati
- Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy; Medical Oncology Unit, University Hospital of Ferrara, Ferrara, Italy
| | - A Schirone
- Medical Oncology Unit, University Hospital of Ferrara, Ferrara, Italy
| | - A Caldara
- Medical Oncology Unit, Ospedale Santa Chiara, Trento, Italy
| | - A Rocca
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy
| | - S Gori
- Sacro Cuore-Don Calabria Hospital, Negrar (VR), Italy
| | - F Piacentini
- Medical Oncology Unit, University Hospital of Modena, Modena, Italy
| | - R Berardi
- Ancona University Hospital, Ancona, Italy
| | - A A Brandes
- Department of Medical Oncology, Azienda USL, Bologna, Italy
| | | | - F Villa
- Hospital of Lecco, Lecco, Italy
| | - R Todeschini
- Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy
| | - M Tognetto
- Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - N Naldi
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - B Bortesi
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - F Montemurro
- Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| | - A Ardizzoni
- Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - L Boni
- Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - A Musolino
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy.
| |
Collapse
|
3
|
Gelsomino F, Tiseo M, Boni L, Cavanna L, Camerini A, Chiari R, Verusio C, Tognetto M, Ardizzoni A. An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Musolino A, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Pellegrino B, Todeschini R, Tognetto M, Naldi N, Bortesi B, Boni L, Montemurro F, Ardizzoni A. Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There are no well-established chemotherapy regimens for metastatic triple negative breast cancer. The combination of a microtubule inhibitor (eribulin) with a nucleoside analog (gemcitabine) may synergistically induce tumor cell death, especially in tumors like triple negative breast cancers (TNBC) characterized by high cell proliferation, aggressive tumor behavior, and chemo-resistance.
Materials and Methods:This is an open-label, national multicenter phase II study evaluating the combination of eribulin (0.88 mg/m2) plus gemcitabine (1000 mg/m2) on day 1 and 8, q21 as either first- or second-line treatment of locally advanced or metastatic TNBC.The primary endpoint was the objective response rate (ORR) for evaluable patients (pts). The study was designed according to the Simon's two stage optimal design. We chose the lower activity (p0) of 0.20 and target activity level (p1) of 0.35. A prospective, molecular correlative study has been being carried out on germinal DNA of study population to assess the role of BRCA mutations and single nucleotide polymorphisms (SNPs) in predicting efficacy and toxicity of the combination regimen.
Results: From July 2013 to September 2016, 83 evaluable pts (37 in the first stage, 46 in the second one) were enrolled. They received a median number of 6 cycles of treatment (range 1-24). The ORR (CR+PR) was 37.35% (90% CI: 28.47-46.93) and the clinical benefit rate (CR+PR+SD ≥ 24wks) was 48.78% (90% CI: 39.24%-58.39%). The most common grade 3-4 adverse events (> 10% of patients) were neutropenia and liver toxicity. With a median follow-up of 28.8 months, the median progression-free survival (PFS) and overall survival (OS) were 5.1 months (95% CI: 4.2-7.0) and 14.7 months (95% CI: 10.2-20.0), respectively. BRCA1/2 deleterious mutations were observed in 15 (22%) out of 68 genotyped pts. Women with BRCA1/2 mutations were associated with worse ORR, PFS and OS than those with BRCA1/2 wild-type. A panel of SNPs in genes of study drug metabolism pathways was evaluated. Among these, CYP3A4 392A >G and FGD4 2044236G>A SNPs were associated with greater liver toxicity by logistic regression analysis. Furthermore, CDA*2 79A>C, RRM1 2455 A>G, and CYP2C8 416G>A SNPs were associated with poorer overall survival by Cox proportional hazards model.
Conclusions:The combination of eribulin and gemcitabine shows promising activity and a moderate toxicity profile in metastatic TNBC. BRCA status and pharmacogenetics tests may help identify pts with high probability of response with negligible toxicity.
Citation Format: Musolino A, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Pellegrino B, Todeschini R, Tognetto M, Naldi N, Bortesi B, Boni L, Montemurro F, Ardizzoni A. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-14-05.
Collapse
Affiliation(s)
- A Musolino
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - L Cavanna
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - D Boggiani
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - C Zamagni
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - A Frassoldati
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - A Caldara
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - A Rocca
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - S Gori
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - F Piacentini
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - R Berardi
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - AA Brandes
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - J Foglietta
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - F Villa
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - B Pellegrino
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - R Todeschini
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - M Tognetto
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - N Naldi
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - B Bortesi
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - L Boni
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - F Montemurro
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - A Ardizzoni
- Medical Oncology Unit and Gruppo Oncologico di Ricerca Clinica (GOIRC), University Hospital of Parma, Parma, Italy; Hospital of Piacenza, Piacenza, Italy; SSD Oncologia Medica Addarii, Bologna, Italy; Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy; Oncologia Medica, Ospedale Santa Chiara, Trento, Italy; IRST-IRCCS, Meldola, Italy; Sacro Cuore-Don Calabria Hospital, Negrar, Italy; University Hospital of Modena, Modena, Italy; Ancona University Hospital, Ancona, Italy; Azienda USL-IRCCS, Bologna, Italy; Hospital of Perugia, Perugia, Italy; Lecco Hospital, Lecco, Italy; GOIRC, Parma, Italy; Careggi University Hospital, ITT, Firenze, Italy; Istituto per la Ricerca e la Cura del Cancro, IRCCS, Candiolo, Italy; Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy
| |
Collapse
|
5
|
Gelsomino F, Tiseo M, Barbieri F, Riccardi F, Cavanna L, Frassoldati A, Delmonte A, Longo L, Dazzi C, Cinieri S, Colantonio I, Tognetto M, Baldari D, Tofani L, Ardizzoni A. Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy298.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
6
|
Musolino A, Gori S, Cavanna L, Graiff C, Frassoldati A, Bria E, Bisagni G, Zambelli A, Partesotti G, Brandes A, Bonetti A, Moscetti L, Zamagni C, Rocca A, Generali D, Montemurro F, Gianni L, Tognetto M, Maglietta G, Todeschini R. Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor-infiltrating lymphocytes (TILs) have been reported to be associated with increased therapeutic efficacy of trastuzumab in the (neo)adjuvant setting for HER2-positive breast cancer (BC). Subcutaneous (SC) trastuzumab has been observed to act at different immunologic levels than IV trastuzumab. Therefore, by modifying the modality of administration of trastuzumab, it could be possible to interfere with different pathways of the immune system and exert a favorable immunomodulation in HER2-positive BC.
Trial design: In this non-comparative, phase II, neoadjuvant, randomized study, patients will be treated with FEC chemotherapy (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) q21 for 3 cycles. Then, they will be randomly assigned in a 1:1 ratio to receive: docetaxel (75 mg/m2) plus pertuzumab (840 mg loading dose, then 420 mg) plus IV trastuzumab (8 mg/kg loading dose, then 6 mg/kg) q21 for 4 cycles (Group A) or, docetaxel plus pertuzumab plus SC trastuzumab (fixed dose of 600 mg) q21 for 4 cycles (Group B). After surgery, study patients will receive trastuzumab q21 x 14 cycles using the same formulation (SC or IV) of the preoperative phase.
Eligibility criteria: Patients must have previously untreated, T2-4d primary HER2-positive BC with no metastatic disease. Other inclusion criteria are: age 18 or older; ECOG performance status 0-1; availability of tumor tissue from diagnostic biopsy; normal left ventricular ejection fraction; normal organ and marrow function.
Specific aims: The main objective of this trial is to evaluate variations of host immune response parameters to either trastuzumab SC or trastuzumab IV given in combination with pertuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive BC. Tumor samples obtained at diagnosis and at definitive surgery will be centrally analyzed for TILs. Blood samples will be also collected during study treatment for tumor-specific lymphocyte cell activity (TLA) analysis. Feasibility, efficacy, safety and health-related quality of life will be also evaluated.
Statistical methods: The primary endpoint is post-surgery pathologic TIL rate on residual disease. The threshold for classifying subjects with high TILs, or not, is defined as equal to 15%, according to the median TIL rate observed in primary HER2-positive tumors. Because this is a phase II study with 2 non-comparative arms, Simon's optimal 2-stage design will be used for each of the 2 study groups. For each arm we assume: p1 = 0.4, expected rate of subjects with high TILs on residual disease, p0 = 0.1, lowest limit of the subject rate (alpha= 0.05; beta= 0.20).
Present accrual and target accrual: A total of 60 patients (first stage: 16 patients) will be enrolled from multiple institutions. From November 29, 2016 to June 11, 2017, 34 patients have been recruited.
Contact information:Dr. Antonino Musolino, MD, MSc, PhD; Medical Oncology Unit, University Hospital of Parma; Tel: +390521702316; Fax: +390521995448; e-mail: amusolino@ao.pr.it. Clinical Trials.gov: NCT03144947.
Citation Format: Musolino A, Gori S, Cavanna L, Graiff C, Frassoldati A, Bria E, Bisagni G, Zambelli A, Partesotti G, Brandes A, Bonetti A, Moscetti L, Zamagni C, Rocca A, Generali D, Montemurro F, Gianni L, Tognetto M, Maglietta G, Todeschini R. Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-03-03.
Collapse
Affiliation(s)
- A Musolino
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - S Gori
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - L Cavanna
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - C Graiff
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - A Frassoldati
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - E Bria
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - G Bisagni
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - A Zambelli
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - G Partesotti
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - A Brandes
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - A Bonetti
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - L Moscetti
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - C Zamagni
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - A Rocca
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - D Generali
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - F Montemurro
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - L Gianni
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - M Tognetto
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - G Maglietta
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| | - R Todeschini
- University Hospital of Parma, Parma, Italy; Ospedale Sacro Cuore – Don Calabria – Negrar (VR), Negrar (VR), Italy; G. da Saliceto Hospital, Piacenza, Italy; Ospedale di Bolzano, Bolzano, Italy; University Hospital of Ferrara, Ferrara, Italy; University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Ospedale di Sassuolo, Modena, Italy; Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy; Azienda ULSS21 Legnago (VR), Legnago (VR), Italy; Hematology and Respiratory Diseases, University Hospital of Modena, Modena, Italy; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Investigative Clinical Oncology, Candiolo Cancer Institute-FPO IRCCS, Candiolo, Italy; Azienda USL di Rimini, Rimini, I
| |
Collapse
|
7
|
Grilli D, Gelsomino F, Massari F, Angelelli B, Tognetto M, Restuccia S, Puggioli C, Ardizzoni A. The impact of the clinical pharmacist (CP) in reporting suspected adverse drug reactions (ADRs): the experience of the Medical Oncology Unit at the S.Orsola-Malpighi University Hospital. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Abstract
Using models of airway diseases, our understanding of the role of tachykinins and kinins in airway pathophysiology has been greatly enhanced by the recent development of a large series of peptide, peptoid and non-peptide antagonists for tachykinin and kinin receptors. This article reviews the experimental findings of the contribution of kinins and tachykinins and their respective receptors, in models of airway inflammation in response to agents known to trigger or worsen asthma attacks, such as antigen and cold air. Some new antagonists, mostly of a non-peptide nature, exhibit excellent pharmacodynamic and pharmacokinetic profiles; a brief account of early clinical studies in which they have been used is also given.
Collapse
Affiliation(s)
- P Geppetti
- Department of Experimental and Clinical Medicine, Pharmacology Unit, University of Ferrara, Via Fossato di Mortara, 19, 44100 Ferrara, Italy.
| | | | | | | | | |
Collapse
|
9
|
Trevisani M, Smart D, Gunthorpe MJ, Tognetto M, Barbieri M, Campi B, Amadesi S, Gray J, Jerman JC, Brough SJ, Owen D, Smith GD, Randall AD, Harrison S, Bianchi A, Davis JB, Geppetti P. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci 2002; 5:546-51. [PMID: 11992116 DOI: 10.1038/nn0602-852] [Citation(s) in RCA: 306] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The vanilloid receptor-1 (VR1) is a heat-gated ion channel that is responsible for the burning sensation elicited by capsaicin. A similar sensation is reported by patients with esophagitis when they consume alcoholic beverages or are administered alcohol by injection as a medical treatment. We report here that ethanol activates primary sensory neurons, resulting in neuropeptide release or plasma extravasation in the esophagus, spinal cord or skin. Sensory neurons from trigeminal or dorsal root ganglia as well as VR1-expressing HEK293 cells responded to ethanol in a concentration-dependent and capsazepine-sensitive fashion. Ethanol potentiated the response of VR1 to capsaicin, protons and heat and lowered the threshold for heat activation of VR1 from approximately 42 degrees C to approximately 34 degrees C. This provides a likely mechanistic explanation for the ethanol-induced sensory responses that occur at body temperature and for the sensitivity of inflamed tissues to ethanol, such as might be found in esophagitis, neuralgia or wounds.
Collapse
Affiliation(s)
- M Trevisani
- Department of Experimental and Clinical Medicine, Headache Center, University of Ferrara, Via Fossato di Mortara 19, 44100 Ferrara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Schmidlin F, Amadesi S, Vidil R, Trevisani M, Martinet N, Caughey G, Tognetto M, Cavallesco G, Mapp C, Geppetti P, Bunnett NW. Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle. Am J Respir Crit Care Med 2001; 164:1276-81. [PMID: 11673222 DOI: 10.1164/ajrccm.164.7.2101157] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Trypsin and mast cell tryptase cleave proteinase-activated receptor 2 (PAR2) to induce alterations in contraction of airway smooth muscle that have been implicated in asthma in experimental animals. Although tryptase inhibitors are under development for treatment of asthma, little is known about the localization and function of PAR2 in human airways. We detected PAR2 expression in primary cultures of human airway smooth muscle cells using reverse transcriptase/polymerase chain reaction (RT-PCR) and immunofluorescence. The PAR2 agonists trypsin, tryptase, and an activating peptide (SLIGKV-NH2) stimulated calcium mobilization in these cells. PAR2 agonists strongly desensitized responses to a second challenge of trypsin and SLIGKV-NH2, but not to thrombin, indicating that they activate a receptor distinct from the thrombin receptors. Immunoreactive PAR2 was detected in smooth muscle, epithelium, glands, and endothelium of human bronchi. Trypsin, SLIGKV-NH2, and tryptase stimulated contraction of isolated human bronchi. Contraction was increased by removal of the epithelium and diminished by indomethacin. Thus, PAR2 is expressed by human bronchial smooth muscle where its activation mobilizes intracellular Ca2+ and induces contraction. These results are consistent with the hypothesis that PAR2 agonists, including tryptase, induce bronchoconstriction of human airway by stimulating smooth muscle contraction. PAR2 antagonists may be useful drugs to prevent bronchoconstriction.
Collapse
MESH Headings
- Bronchi/chemistry
- Bronchi/drug effects
- Bronchi/metabolism
- Cells, Cultured
- Humans
- Macrophages/physiology
- Muscle Contraction/drug effects
- Muscle, Smooth/chemistry
- Muscle, Smooth/drug effects
- Muscle, Smooth/metabolism
- RNA, Messenger/analysis
- Receptor, PAR-2
- Receptors, Thrombin/agonists
- Receptors, Thrombin/biosynthesis
- Receptors, Thrombin/genetics
- Receptors, Thrombin/physiology
Collapse
Affiliation(s)
- F Schmidlin
- Department of Surgery, and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, California 94143-0660, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
De Petrocellis L, Harrison S, Bisogno T, Tognetto M, Brandi I, Smith GD, Creminon C, Davis JB, Geppetti P, Di Marzo V. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem 2001; 77:1660-3. [PMID: 11413249 DOI: 10.1046/j.1471-4159.2001.00406.x] [Citation(s) in RCA: 160] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The endogenous cannabinoid receptor ligand, anandamide (AEA), is a full agonist of the vanilloid receptor type 1 (VR1) for capsaicin. Here, we demonstrate that the potency and efficacy of AEA at VR1 receptors can be significantly increased by the concomitant activation of protein kinase A (PKA). In human embryonic kidney (HEK) cells over-expressing human VR1, AEA induces a rise in cytosolic Ca(2+) concentration that is mediated by this receptor. The EC(50) for this effect was decreased five-fold in the presence of forskolin (FRSK, 1-5 microM) or the cAMP analogue, 8-Br-cAMP (10-100 microM). The effects of 8-Br-cAMP and FRSK were blocked by a selective PKA inhibitor. The FRSK (10 nM) also potently enhanced the sensory neurone- and VR1-mediated constriction by AEA of isolated guinea-pig bronchi, and this effect was abolished by a PKA inhibitor. In rat dorsal root ganglia slices, AEA-induced release of substance P, an effect mediated by VR1 activation, was enhanced three-fold by FRSK (10 nM). Thus, the ability of AEA to stimulate sensory VR1, with subsequent neuropeptide release, appears to be regulated by the state of activation of PKA. This observation supports the hypothesis that endogenous AEA might stimulate VR1 under certain pathophysiological conditions.
Collapse
Affiliation(s)
- L De Petrocellis
- Endocannabinoid Research Group, Istituto di Cibernetica (LDP), Consiglio Nazionale delle Ricerche, Arco Felice, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
McRoberts JA, Coutinho SV, Marvizón JC, Grady EF, Tognetto M, Sengupta JN, Ennes HS, Chaban VV, Amadesi S, Creminon C, Lanthorn T, Geppetti P, Bunnett NW, Mayer EA. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001; 120:1737-48. [PMID: 11375955 DOI: 10.1053/gast.2001.24848] [Citation(s) in RCA: 164] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND & AIMS N-methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that have an important role in long-term potentiation and memory processing in the central nervous system. The aims in this study were to determine whether NMDA receptors are expressed in the peripheral nervous system and identify their role in mediating behavioral pain responses to colonic distention in the normal gut. METHODS AND RESULTS Immunohistochemical localization of the NR1 subunit showed that NMDA receptors are expressed on the cell bodies and peripheral terminals of primary afferent nerves innervating the colon. Dorsal root ganglia neurons retrogradely labeled from the colon in short-term culture responded to addition of NMDA with increased intracellular [Ca2+]. Activation of peripheral NMDA receptors in colonic tissue sections caused Ca2+-dependent release of the proinflammatory neuropeptides, calcitonin gene-related peptide and substance P. Behavioral pain responses to noxious mechanical stimulation were inhibited in a reversible, dose-dependent manner by intravenous administration of memantine, a noncompetitive antagonist of the NMDA receptor. Single fiber recordings of decentralized pelvic nerves showed that colorectal distention responsive afferent nerve activity was inhibited by memantine. CONCLUSIONS Peripheral NMDA receptors are important in normal visceral pain transmission, and may provide a novel mechanism for development of peripheral sensitization and visceral hyperalgesia.
Collapse
Affiliation(s)
- J A McRoberts
- UCLA/CURE Neuroenteric Disease Program and Department of Medicine, University of California, Los Angeles, California 90073, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Amadesi S, Moreau J, Tognetto M, Springer J, Trevisani M, Naline E, Advenier C, Fisher A, Vinci D, Mapp C, Miotto D, Cavallesco G, Geppetti P. NK1 receptor stimulation causes contraction and inositol phosphate increase in medium-size human isolated bronchi. Am J Respir Crit Care Med 2001; 163:1206-11. [PMID: 11316660 DOI: 10.1164/ajrccm.163.5.2002079] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Although contraction of human isolated bronchi is mediated mainly by tachykinin NK2 receptors, NK1 receptors, via prostanoid release, contract small-size (approximately 1 mm in diameter) bronchi. Here, we have investigated the presence and biological responses of NK1 receptors in medium-size (2-5 mm in diameter) human isolated bronchi. Specific staining was seen in bronchial sections with an antibody directed against the human NK1 receptor. The selective NK1 receptor agonist, [Sar(9), Met(O2)(11)]SP, contracted about 60% of human isolated bronchial rings. This effect was reduced by two different NK1 receptor antagonists, CP-99,994 and SR 140333. Contraction induced by [Sar(9), Met(O2)(11)]SP was independent of acetylcholine and histamine release and epithelium removal, and was not affected by nitric oxide synthase and cyclooxygenase (COX) inhibition. [Sar(9), Met(O2)(11)]SP increased inositol phosphate (IP) levels, and SR 140333 blocked this increase, in segments of medium- and small-size (approximately 1 mm in diameter) human bronchi. COX inhibition blocked the IP increase induced by [Sar(9), Met(O2)(11)]SP in small-size, but not in medium-size, bronchi. NK1 receptors mediated bronchoconstriction in a large proportion of medium-size human bronchi. Unlike small-size bronchi this effect is independent of prostanoid release, and the results are suggestive of a direct activation of smooth muscle receptors and IP release.
Collapse
Affiliation(s)
- S Amadesi
- Pharmacology Unit, Department of Experimental and Clinical Medicine, University of Ferrara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, Matera M, Geppetti P, Bianchi A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 2001; 21:1104-9. [PMID: 11160380 PMCID: PMC6762236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
Recently, the cannabinoid (CB) receptor agonist anandamide (AEA) has been shown to excite perivascular terminals of primary sensory neurons via activation of the vanilloid receptor-1 (VR-1). To determine whether AEA stimulates central terminals of these neurons, via VR-1 activation, we studied the release of calcitonin gene-related peptide (CGRP)- and substance P (SP)-like immunoreactivities (LI) from slices of rat dorsal spinal cord. Mobilization of Ca(2+) in rat dorsal root ganglion (DRG) neurons in culture was also studied. AEA (0.1-10 micrometer) increased the outflow of CGRP-LI and SP-LI from slices of the rat dorsal spinal cord in a Ca(2+)-dependent manner and increased [Ca(2+)](i) in capsaicin-sensitive cultured DRG neurons. Both effects of AEA were abolished by capsaicin pretreatment and by the VR-1 antagonist capsazepine but not affected by the CB receptor antagonists AM281 or AM630. Both neuropeptide release and Ca(2+) mobilization induced by electrical field stimulation (EFS) were inhibited by a low concentration of AEA (10 nm). Inhibition by AEA of EFS-induced responses was reversed by AM281 and AM630, but was not affected by capsazepine. Results indicate that stimulation of VR-1 with high concentrations of AEA excites central terminals of capsaicin-sensitive DRG neurons, thus causing neuropeptide release in the dorsal spinal cord. This novel activity opposes the CB receptor-mediated inhibitory action of low concentrations AEA. However, only if large amounts of endogenous AEA could be produced at the level of the dorsal spinal cord, they may not inhibit, but rather activate, nociceptive sensory neurons.
Collapse
MESH Headings
- Animals
- Arachidonic Acids/pharmacology
- Calcitonin Gene-Related Peptide/metabolism
- Calcium/metabolism
- Capsaicin/analogs & derivatives
- Capsaicin/pharmacology
- Dose-Response Relationship, Drug
- Electric Stimulation
- Endocannabinoids
- Ganglia, Spinal/cytology
- Ganglia, Spinal/drug effects
- Ganglia, Spinal/metabolism
- In Vitro Techniques
- Male
- Neurons, Afferent/cytology
- Neurons, Afferent/drug effects
- Neurons, Afferent/metabolism
- Polyunsaturated Alkamides
- Presynaptic Terminals/drug effects
- Rats
- Receptors, Cannabinoid
- Receptors, Drug/agonists
- Receptors, Drug/antagonists & inhibitors
- Receptors, Drug/metabolism
- Spinal Cord/cytology
- Spinal Cord/drug effects
- Spinal Cord/metabolism
- Substance P/metabolism
- TRPV Cation Channels
Collapse
Affiliation(s)
- M Tognetto
- Headache Center, Departments of Experimental and Clinical Medicine and Neuroscience, University of Ferrara and Sant'Anna Hospital, 44100 Ferrara, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ricciardolo FL, Steinhoff M, Amadesi S, Guerrini R, Tognetto M, Trevisani M, Creminon C, Bertrand C, Bunnett NW, Fabbri LM, Salvadori S, Geppetti P. Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. Am J Respir Crit Care Med 2000; 161:1672-80. [PMID: 10806174 DOI: 10.1164/ajrccm.161.5.9907133] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The protease activated receptor-2 (PAR-2) belongs to a family of G-protein-coupled receptors that are activated by proteolysis. Trypsin cleaves PAR-2, exposing an N-terminal tethered ligand (SLIGRL) that activates the receptor. Messenger RNA (mRNA) for PAR-2 was found in guinea pig airway tissue by reverse transcription-polymerase chain reaction, and PAR-2 was found by immunohistochemistry in airway epithelial and smooth-muscle cells. In anesthetized guinea pigs, trypsin and SLIGRL-NH(2) (given intratracheally or intravenously) caused a bronchoconstriction that was inhibited by the combination of tachykinin-NK(1) and -NK(2) receptor antagonists and was potentiated by inhibition of nitric oxide synthase (NOS). Trypsin and SLIGRL-NH(2) relaxed isolated trachea and main bronchi, and contracted intrapulmonary bronchi. Relaxation of main bronchi was abolished or reversed to contraction by removal of epithelium, administration of indomethacin, and NOS inhibition. PAR-1, PAR-3, and PAR-4 were not involved in the bronchomotor action of either trypsin or SLIGRL-NH(2), because ligands of these receptors were inactive either in vitro or in vivo, and because thrombin (a PAR-1 and PAR-3 agonist) did not show cross-desensitization with PAR-2 agonists in vivo. Thus, we have localized PAR-2 to the guinea-pig airways, and have shown that activation of PAR-2 causes multiple motor effects in these airways, including in vivo bronchoconstriction, which is in part mediated by a neural mechanism.
Collapse
Affiliation(s)
- F L Ricciardolo
- Department of Experimental and Clinical Medicine and Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6:151-8. [PMID: 10655102 DOI: 10.1038/72247] [Citation(s) in RCA: 742] [Impact Index Per Article: 30.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Trypsin and mast cell tryptase cleave proteinase-activated receptor 2 and, by unknown mechanisms, induce widespread inflammation. We found that a large proportion of primary spinal afferent neurons, which express proteinase-activated receptor 2, also contain the proinflammatory neuropeptides calcitonin gene-related peptide and substance P. Trypsin and tryptase directly signal to neurons to stimulate release of these neuropeptides, which mediate inflammatory edema induced by agonists of proteinase-activated receptor 2. This new mechanism of protease-induced neurogenic inflammation may contribute to the proinflammatory effects of mast cells in human disease. Thus, tryptase inhibitors and antagonists of proteinase-activated receptor 2 may be useful anti-inflammatory agents.
Collapse
Affiliation(s)
- M Steinhoff
- Department of Surgery and Physiology, University of California, San Francisco, CA 94143, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Rizzi A, Calò G, Trevisani M, Tognetto M, Fabbri L, Mapp C, Guerrini R, Salvadori S, Regoli D, Geppetti P. Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. Life Sci 1999; 64:PL157-63. [PMID: 10210279 DOI: 10.1016/s0024-3205(99)00045-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
We studied the action of nociceptin (NC) on the atropine-resistant contractions of the guinea pig isolated bronchus evoked by the electrical field stimulation (EFS), an effect that is mediated by the activation of excitatory non adrenergic-non cholinergic (eNANC) nerves and the subsequent release of tachykinins. The functional site by which NC acts in this preparation was investigated using few different NC receptor agonists and the newly discovered NC receptor antagonist, [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2 ([F/G]NC(1-13)NH2). NC inhibited in a concentration dependent manner (pEC50 7.14; Em - 87 +/- 3% of control values) EFS induced contractions. NC effect was mimicked by the NC analogues, NCNH2 and NC(1-13)NH2, but not by NC(1-9)NH2. NC (1 microM) did not affect the contractile effects of exogenously applied neurokinin A (1 microM). [F/G]NC(1-13)NH2 (10 microM) completely prevented the inhibition induced by NC (1 microM), whereas naloxone (1 microM) was found inactive. Both naloxone and ([F/G]NC(1-13)NH2 were per se inactive on basal resting tone as well as on the electrically induced contractions. The present findings show that NC inhibits the atropine-resistant EFS-induced contraction in the guinea pig bronchus by inhibiting eNANC nerves, and suggest the presence of NC receptors, distinct from opioid receptors, on the nerves of the guinea pig bronchus.
Collapse
Affiliation(s)
- A Rizzi
- Department of Experimental and Clinical Medicine, University of Ferrara, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|